Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
BB BIOTECH AG |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 41.35 CHF | +0.12% | -2.59% | -25.09% | |
| Aug. 21 | BB Biotech Shares to be Suspended from Euronext Star Milan Pending Delisting | MT |
| Jul. 21 | BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
| Sales 2023 * | -56 M -61 M | Sales 2024 * | 32 M 35 M | Capitalization | 2 268 M 2 477 M |
|---|---|---|---|---|---|
| Net income 2023 * | -196 M -214 M | Net income 2024 * | 26 M 28 M | EV / Sales 2023 * | -47,1x |
| Net Debt 2023 * | 352 M 385 M | Net Debt 2024 * | 346 M 377 M | EV / Sales 2024 * | 81,4x |
| P/E ratio 2023 * | -15,6x | P/E ratio 2024 * | 76,6x | Employees | - |
| Yield 2023 * | 6,89% | Yield 2024 * | 5,47% | Free-Float | 97.24% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.12% | ||
| 1 week | -2.59% | ||
| Current month | +0.73% | ||
| 1 month | +2.86% | ||
| 3 months | +6.16% | ||
| 6 months | -17.30% | ||
| Current year | -25.09% |
1 week
40.75
42.45
1 month
40.0044.80
Current year
38.2560.80
1 year
38.2560.80
3 years
38.2593.45
5 years
38.2593.45
10 years
24.6093.45
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-29 | 41.35 | +0.12% | 51,231 |
| 23-09-28 | 41.30 | +0.73% | 49,091 |
| 23-09-27 | 41.00 | -0.24% | 48,479 |
| 23-09-26 | 41.10 | -1.67% | 24,783 |
| 23-09-25 | 41.80 | -1.53% | 38,893 |
Delayed Quote Swiss Exchange, September 29, 2023 at 11:30 am EDT
More quotes
BB Biotech is a portfolio company that specializes in investments in biotechnology companies. At the end of 2018, the stock portfolio, assessed at market value to be EUR3,064.2 million, breaks down by type of holding as follows:
- listed companies (99.9%): primarily Ionis Pharmaceuticals (rare diseases), Gilead Sciences (infectious viral diseases and flu), Celgene Corporation (cancer and inflammation of the immune system), Esperion Therapeutics (cardio-metabolic diseases), Vertex Pharmaceuticals (infectious diseases and diseases of the immune system) and Incyte (cancers, hematologic disorders and inflammatory diseases);
- other (0.1%).
Calendar
2023-10-20
- Q3 2023 Earnings Release
Trading Rating :
Investor Rating :
ESG Refinitiv :
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
41.35CHF
Average target price
65.90CHF
Spread / Average Target
+59.37%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -25.09% | 2 480 M $ | |
| +115.74% | 91 M $ | |
| +0.99% | 50 M $ | |
| +36.03% | 247 M $ | |
| -.--% | 1 789 M $ | |
| -54.24% | 60 M $ | |
| -12.06% | 620 M $ | |
| -39.18% | 796 M $ | |
| -59.44% | 132 M $ | |
| +22.70% | 897 M $ |
